Clinical trials: Skin Irritation
Acne Vulgaris
A Study of Different Use Regimens Using Two Acne Treatments
A study to determine if using 2 acne products in the morning is as safe and efficacious as using one product in the morning and one product in the evening.
- Trial name
- NCT00907257
- Testing
- benzoyl peroxide wash, Tretinoin gel
- Where
- 12 sites in United States
- Volunteers
- 247 people
- Sponsor
- Bausch Health Americas, Inc.
Osteoporosis, Postmenopausal
A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered Transdermally in Healthy Postmenopausal Women
This study is a Phase 1, multi-center, 2-part, subject- and investigator-blind, randomized, placebo-controlled, multiple dose study of transdermal teriparatide (80-µg dose) in healthy postmenopausal women.
- Trial name
- NCT01250145
- Testing
- LY333334
- Where
- 5 sites in United States, Germany and 1 more
- Volunteers
- 251 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis (AD)
Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema
The purpose of this 14-day, two phase clinical study is to test the tolerance of a new over-the-counter moisturizing balm on subjects with eczema.
- Trial name
- NCT02357940
- Testing
- Experimental Product
- Where
- 2 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Acne Vulgaris
A Study of Acne Treatment in Children Ages 9 to 11
A study to determine if using Retin-A Micro 0.04% as facial acne treatment in patients ages 9 to 11 is safe and efficacious.
- Trial name
- NCT00907335
- Testing
- Retin-A Micro 0.04% facial acne treatment, Vehicle control
- Where
- 12 sites in United States
- Volunteers
- 110 people
- Sponsor
- Bausch Health Americas, Inc.
Acne Vulgaris
A Study of a New Drug Treatment for Acne
A study to determine if three different doses of a new acne treatment are safe and better at reducing facial acne than a treatment without active ingredient.
- Trial name
- NCT01326780
- Testing
- 1.2% JNJ 10229570-AAA, 2.4% JNJ 10229570-AAA, 3.6% JNJ 10229570-AAA
- Where
- 18 sites in United States
- Volunteers
- 431 people
- Sponsor
- Bausch Health Americas, Inc.